HLB Group IR Day Showcases Pipeline Progress, FDA Milestones, and New Business Plans

Chairman Jin Yang-gon delivers a presentation at HLB IR Day. (Photo courtesy of HLB Group)

 

HLB Group hosted its “2026 IR Day” in Seoul, bringing together institutional investors and analysts to outline its long-term growth strategy and affiliate operations. Chairman Jin Yang-gon introduced key concepts such as the Rhizome approach and “point-line-plane” strategy, while 10 listed affiliates presented their business updates through individual briefings, integrated sessions, and joint Q&A discussions.

Investor focus centered on upcoming R&D and regulatory milestones, including Phase 1 CAR-T data at the American Association for Cancer Research Annual Meeting, Phase 3 trial results for a neurotrophic keratitis treatment, and potential U.S. FDA decisions on liver and bile duct cancer therapies later this year. The group also highlighted new business initiatives across subsidiaries and emphasized plans to strengthen synergy, with an additional retail investor event scheduled in Seoul to further communicate its strategy.

Read more: https://www.ittimes.com/news/articleView.html?idxno=84107

HLB Group Holds IR Day, Bringing Together CEOs of 10 Listed Affiliates - IT타임스